- Home
- FMST vs RDHL Comparison
FMST vs RDHL Comparison
Compare FMST & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- RDHL
- Stock Information
- Founded
- FMST 2005
- RDHL 2009
- Country
- FMST Canada
- RDHL Israel
- Employees
- FMST N/A
- RDHL N/A
- Industry
- FMST Other Metals and Minerals
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- RDHL Health Care
- Exchange
- FMST Nasdaq
- RDHL Nasdaq
- Market Cap
- FMST 15.9M
- RDHL 13.1M
- IPO Year
- FMST N/A
- RDHL N/A
- Fundamental
- Price
- FMST $2.39
- RDHL $7.97
- Analyst Decision
- FMST
- RDHL
- Analyst Count
- FMST 0
- RDHL 0
- Target Price
- FMST N/A
- RDHL N/A
- AVG Volume (30 Days)
- FMST 6.9K
- RDHL 26.7K
- Earning Date
- FMST 01-01-0001
- RDHL 10-15-2024
- Dividend Yield
- FMST N/A
- RDHL N/A
- EPS Growth
- FMST N/A
- RDHL N/A
- EPS
- FMST N/A
- RDHL N/A
- Revenue
- FMST N/A
- RDHL $3,707,000.00
- Revenue This Year
- FMST N/A
- RDHL $224.90
- Revenue Next Year
- FMST N/A
- RDHL $82.69
- P/E Ratio
- FMST N/A
- RDHL N/A
- Revenue Growth
- FMST N/A
- RDHL N/A
- 52 Week Low
- FMST $1.77
- RDHL $6.43
- 52 Week High
- FMST $4.25
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- FMST 25.62
- RDHL 39.80
- Support Level
- FMST $2.47
- RDHL $7.95
- Resistance Level
- FMST $2.95
- RDHL $8.50
- Average True Range (ATR)
- FMST 0.23
- RDHL 0.43
- MACD
- FMST -0.06
- RDHL -0.09
- Stochastic Oscillator
- FMST 1.10
- RDHL 0.84
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Lithium Resource & Technology Ltd is a hard-rock exploration company strategically located to capitalize on the growing EV appetite and is committed to being a supplier of North America's lithium feedstock. As the transition towards decarbonization, the company is focused on the exploration and growth of its five Lithium Lane Projects in Snow Lake Manitoba. It also has the Winston Gold/Silver Property in New Mexico, USA. The company mainly operates in one reportable operating segment being the acquisition and exploration of exploration and evaluation assets.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.